AI for Humanity

Peter Gault founded Quill.org with a core belief that writing is a superpower. In 2014, Gault — a former school debate team member — envisioned a tool to enhance students' critical thinking skills and inspire meaningful, thoughtful discourse. As he pursued this mission, he recognized that the journey would start by equipping young people with strong foundational reading, writing, and critical thinking skills to help them express their ideas effectively. Quill.org is an AI-powered nonprofit designed to do just that.

The organization is redefining AI-powered, 1:1 literacy tutoring focused on supporting students in underserved Title I schools across the U.S. Since its launch, Quill has reached over 9M students, including 6M in low-income schools, bridging the literacy gap through accessible, high-quality coaching and feedback. Peter’s vision? A world where responsible, customized AI plays a pivotal role in creating educational equity for all students.

Atif Javed had a vision: break down language barriers that refugees face daily. That vision became Tarjimly. The APN offers machine-generated translation, helping volunteers instantly communicate with aid workers as they support the world’s 30M+ refugees. Whether a refugee needs to speak with a doctor, lawyer, or aid worker, Tarjimly makes it happen — anonymously and instantly via mobile app or SMS. The platform is multimodal, so refugees can send texts, photos, or even hop on a video call.

But it’s not just about helping refugees. Tarjimly empowers bilingual people around the world to volunteer as translators – from anywhere. At the same time, they’re leveraging volunteers to correct data that trains LLMs for 55 low-resourced languages. Atif is proving that AI can make a real, global impact.

Laura Kleiman lost her mother to cancer and committed to changing outcomes for other families. After earning her PhD in Computational and Systems Biology from MIT, she realized AI could accelerate cancer treatment discovery. So, she founded Reboot Rx. The APN uses a suite of tools — like fine-tuned BERT models and biomedical information extraction — to scan medical research and identify affordable, generic drugs for certain cancers. Reboot Rx’s model ranks the best drug candidates, ensuring only the most promising move forward.

With 20 million new cases a year and care costs hitting $1 trillion, the stakes are high. But Reboot Rx is moving potential treatments from research labs to clinical trials — and into patients’ hands — faster.